ATA17892000A - Vakzin-zusammensetzung - Google Patents

Vakzin-zusammensetzung

Info

Publication number
ATA17892000A
ATA17892000A AT0178900A AT17892000A ATA17892000A AT A17892000 A ATA17892000 A AT A17892000A AT 0178900 A AT0178900 A AT 0178900A AT 17892000 A AT17892000 A AT 17892000A AT A17892000 A ATA17892000 A AT A17892000A
Authority
AT
Austria
Prior art keywords
peptide
amino acid
acid residue
group
antigen
Prior art date
Application number
AT0178900A
Other languages
English (en)
Other versions
AT410635B (de
Original Assignee
Cistem Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT0178900A priority Critical patent/AT410635B/de
Application filed by Cistem Biotechnologies Gmbh filed Critical Cistem Biotechnologies Gmbh
Priority to PT01980496T priority patent/PT1326634E/pt
Priority to KR1020037004977A priority patent/KR100598302B1/ko
Priority to CZ20031299A priority patent/CZ303303B6/cs
Priority to PCT/EP2001/012041 priority patent/WO2002032451A1/en
Priority to US10/399,442 priority patent/US8361476B2/en
Priority to AU1232602A priority patent/AU1232602A/xx
Priority to SI200130564T priority patent/SI1326634T1/sl
Priority to BR0114994-6 priority patent/BRPI0114994B8/pt
Priority to ES01980496T priority patent/ES2263668T3/es
Priority to HU0302117A priority patent/HU228382B1/hu
Priority to RU2003114434/15A priority patent/RU2328305C2/ru
Priority to SK575-2003A priority patent/SK287618B6/sk
Priority to AU2002212326A priority patent/AU2002212326B2/en
Priority to AT01980496T priority patent/ATE324116T1/de
Priority to NZ524532A priority patent/NZ524532A/en
Priority to DK01980496T priority patent/DK1326634T3/da
Priority to DE60119145T priority patent/DE60119145T2/de
Priority to EP01980496A priority patent/EP1326634B1/de
Priority to JP2002535688A priority patent/JP4227407B2/ja
Priority to MXPA03002828A priority patent/MXPA03002828A/es
Priority to CNB018171168A priority patent/CN1248736C/zh
Priority to PL362966A priority patent/PL209016B1/pl
Priority to IL15460501A priority patent/IL154605A0/xx
Priority to CA2426490A priority patent/CA2426490C/en
Priority to HK03108189.1A priority patent/HK1055899B/en
Publication of ATA17892000A publication Critical patent/ATA17892000A/de
Priority to IS6722A priority patent/IS2608B/is
Priority to ZA200301465A priority patent/ZA200301465B/en
Priority to IL154605A priority patent/IL154605A/en
Priority to NO20031595A priority patent/NO330274B1/no
Application granted granted Critical
Publication of AT410635B publication Critical patent/AT410635B/de
Priority to RU2007146372/15A priority patent/RU2007146372A/ru
Priority to US12/124,785 priority patent/US8900564B2/en
Priority to JP2008134215A priority patent/JP2008222721A/ja
Priority to US13/742,500 priority patent/US20130216583A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT0178900A 2000-10-18 2000-10-18 Vakzin-zusammensetzung AT410635B (de)

Priority Applications (34)

Application Number Priority Date Filing Date Title
AT0178900A AT410635B (de) 2000-10-18 2000-10-18 Vakzin-zusammensetzung
KR1020037004977A KR100598302B1 (ko) 2000-10-18 2001-10-18 백신 조성물
CZ20031299A CZ303303B6 (cs) 2000-10-18 2001-10-18 Složená vakcína
PCT/EP2001/012041 WO2002032451A1 (en) 2000-10-18 2001-10-18 Vaccine composition comprising an antigen and a peptide having adjuvant properties
US10/399,442 US8361476B2 (en) 2000-10-18 2001-10-18 Vaccine composition comprising an antigen and a peptide having adjuvant properties
AU1232602A AU1232602A (en) 2000-10-18 2001-10-18 Vaccine composition
SI200130564T SI1326634T1 (sl) 2000-10-18 2001-10-18 Vakcinski sestavek, ki obsega antigen in peptid zadjuvantnimi lastnostmi
BR0114994-6 BRPI0114994B8 (pt) 2000-10-18 2001-10-18 composição de vacina
ES01980496T ES2263668T3 (es) 2000-10-18 2001-10-18 Composicion de vacuna que comprende un antigeno y un peptido con propiedades adyuvantes.
HU0302117A HU228382B1 (en) 2000-10-18 2001-10-18 Vaccine composition
RU2003114434/15A RU2328305C2 (ru) 2000-10-18 2001-10-18 Вакцинная композиция
SK575-2003A SK287618B6 (sk) 2000-10-18 2001-10-18 Vakcína obsahujúca aspoň jeden antigén a peptid a použitie tohto peptidu
AU2002212326A AU2002212326B2 (en) 2000-10-18 2001-10-18 Vaccine composition comprising an antigen and a peptide having adjuvant properties
AT01980496T ATE324116T1 (de) 2000-10-18 2001-10-18 Ein antigen und ein adjuvans-peptid enthaltende impfstoffzusammensetzung
NZ524532A NZ524532A (en) 2000-10-18 2001-10-18 Vaccine composition
DK01980496T DK1326634T3 (da) 2000-10-18 2001-10-18 Vaccinepræparat der omfatter et antigen og et peptid med adjuvansegenskaber
PT01980496T PT1326634E (pt) 2000-10-18 2001-10-18 Composicao de vacina compreendendo um antigenio e um peptido possuindo propriedades adjuvantes
DE60119145T DE60119145T2 (de) 2000-10-18 2001-10-18 Ein antigen und ein adjuvans-peptid enthaltende impfstoffzusammensetzung
EP01980496A EP1326634B1 (de) 2000-10-18 2001-10-18 Ein antigen und ein adjuvans-peptid enthaltende impfstoffzusammensetzung
MXPA03002828A MXPA03002828A (es) 2000-10-18 2001-10-18 Composicion de vacuna.
CNB018171168A CN1248736C (zh) 2000-10-18 2001-10-18 疫苗组合物
PL362966A PL209016B1 (pl) 2000-10-18 2001-10-18 Kompozycja szczepionek i zastosowanie polipeptydu do wytwarzania adiuwantu lub białka nośnikowego
IL15460501A IL154605A0 (en) 2000-10-18 2001-10-18 Vaccine composition
CA2426490A CA2426490C (en) 2000-10-18 2001-10-18 Vaccine composition comprising an antigen and a peptide having adjuvant properties
HK03108189.1A HK1055899B (en) 2000-10-18 2001-10-18 Vaccine composition comprising an antigen and a peptide having adjuvant properties
JP2002535688A JP4227407B2 (ja) 2000-10-18 2001-10-18 ワクチン組成物
IS6722A IS2608B (is) 2000-10-18 2003-02-20 Bóluefnissamsetning sem samanstendur af mótefnisvaka og peptíði sem hefur ónæmisglæðandi eiginleika.
IL154605A IL154605A (en) 2000-10-18 2003-02-24 A preparation that includes a peptide that is able to increase the immune response to the antigen given - jointly
ZA200301465A ZA200301465B (en) 2000-10-18 2003-02-24 Vaccine composition comprising an antigen and a peptide having adjuvant properties.
NO20031595A NO330274B1 (no) 2000-10-18 2003-04-08 Vaksine som omfatter minst ett antigen og et peptid med gitt sekvens, og anvendelse av peptidet til fremstilling av en adjuvans eller et baereprotein
RU2007146372/15A RU2007146372A (ru) 2000-10-18 2007-12-13 Вакцинная композиция
US12/124,785 US8900564B2 (en) 2000-10-18 2008-05-21 Vaccine composition comprising an antigen and a peptide having adjuvant properties
JP2008134215A JP2008222721A (ja) 2000-10-18 2008-05-22 ワクチン組成物
US13/742,500 US20130216583A1 (en) 2000-10-18 2013-01-16 Vaccine composition comprising an antigen and a peptide having adjuvant properties

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0178900A AT410635B (de) 2000-10-18 2000-10-18 Vakzin-zusammensetzung

Publications (2)

Publication Number Publication Date
ATA17892000A true ATA17892000A (de) 2002-11-15
AT410635B AT410635B (de) 2003-06-25

Family

ID=3688953

Family Applications (2)

Application Number Title Priority Date Filing Date
AT0178900A AT410635B (de) 2000-10-18 2000-10-18 Vakzin-zusammensetzung
AT01980496T ATE324116T1 (de) 2000-10-18 2001-10-18 Ein antigen und ein adjuvans-peptid enthaltende impfstoffzusammensetzung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01980496T ATE324116T1 (de) 2000-10-18 2001-10-18 Ein antigen und ein adjuvans-peptid enthaltende impfstoffzusammensetzung

Country Status (26)

Country Link
US (3) US8361476B2 (de)
EP (1) EP1326634B1 (de)
JP (2) JP4227407B2 (de)
KR (1) KR100598302B1 (de)
CN (1) CN1248736C (de)
AT (2) AT410635B (de)
AU (2) AU1232602A (de)
BR (1) BRPI0114994B8 (de)
CA (1) CA2426490C (de)
CZ (1) CZ303303B6 (de)
DE (1) DE60119145T2 (de)
DK (1) DK1326634T3 (de)
ES (1) ES2263668T3 (de)
HU (1) HU228382B1 (de)
IL (2) IL154605A0 (de)
IS (1) IS2608B (de)
MX (1) MXPA03002828A (de)
NO (1) NO330274B1 (de)
NZ (1) NZ524532A (de)
PL (1) PL209016B1 (de)
PT (1) PT1326634E (de)
RU (2) RU2328305C2 (de)
SI (1) SI1326634T1 (de)
SK (1) SK287618B6 (de)
WO (1) WO2002032451A1 (de)
ZA (1) ZA200301465B (de)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT410635B (de) * 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
WO2002053184A2 (en) * 2001-01-05 2002-07-11 Intercell Ag Uses for polycationic compounds as vaccine adjuvants
EP1347775B1 (de) 2001-01-05 2016-11-30 Valneva Austria GmbH Gebrauch von polykationischen substanzen als adjuvantien für impfstoffe
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
EP1279404A1 (de) 2001-07-26 2003-01-29 Istituto Superiore di Sanità Verwendung von HIV-1 Fragmenten oder Derivaten zur Bestimmung oder Aktivierung von Antigen-präsentierenden Zellen, oder zur Abgabe von Cargo-Molekülen für Impfung oder für Behandlung von anderen Erkrankungen
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
JP2005533855A (ja) 2002-07-24 2005-11-10 インターツェル・アクチェンゲゼルシャフト 病原性ウイルスからの別のリーディングフレームによりコードされる抗原
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
EP1537418A2 (de) 2002-09-13 2005-06-08 Intercell AG Verfahren zur isolierung von hepatitis c virus peptiden
JP5116971B2 (ja) 2002-10-15 2013-01-09 インターセル アーゲー Ｂ群連鎖球菌の接着因子をコードする核酸、ｂ群連鎖球菌の接着因子、およびその使用
CN1756843B (zh) 2003-03-04 2012-03-21 英特塞尔股份公司 化脓链球菌抗原
ES2351489T3 (es) * 2003-03-24 2011-02-07 Intercell Ag Vacunas mejoradas.
AU2004224746B2 (en) * 2003-03-24 2009-04-23 Valneva Austria Gmbh Improved vaccines
AU2004226262A1 (en) 2003-03-31 2004-10-14 Intercell Ag Staphylococcus epidermidis antigens
US7635487B2 (en) 2003-04-15 2009-12-22 Intercell Ag S. pneumoniae antigens
US8076059B2 (en) 2003-04-16 2011-12-13 Duke University Adjuvant capable of specifically activating the adaptive immune response
EP1620460A2 (de) 2003-05-07 2006-02-01 Intercell AG Streptococcus agalactiae-antigene i + ii
EP1629005A2 (de) 2003-05-30 2006-03-01 Intercell AG Antigene aus enterococcus
CA2530062A1 (en) * 2003-07-11 2005-01-20 Intercell Ag Hcv vaccines
EP1722819B1 (de) 2004-03-12 2007-12-26 Intercell AG Verfahren zur solubilisierung von peptid-mischungen
EP2149583B1 (de) 2004-09-24 2015-10-28 Novartis AG Modifiziertes VP1-Capsid Protein von Parvovirus B19
DK1931379T3 (da) 2005-10-07 2013-08-19 Sec Dep For Health Proteiner med forbedret opløselighed samt fremgangsmåder til frembringelse og anvendelse af samme
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
KR20090024292A (ko) 2006-06-28 2009-03-06 스태튼스 세룸 인스티튜트 단백질 단편 또는 펩타이드 혼합물로서 전달되는 항원을 가진 백신접종에 의해 준우성 항원결정기를 포함하는 ｔ세포 레퍼토리 확장
EP2292647A3 (de) 2006-07-07 2011-06-08 Intercell AG Kleine Streptococcus-pyogenes-Antigene und Verwendung dafür
EP2289906A1 (de) 2006-09-15 2011-03-02 Intercell AG Borrelia-Antigene
EP1923069A1 (de) 2006-11-20 2008-05-21 Intercell AG Schutzpeptide gegen S. pneumoniae und diesbezügliche Zusammensetzungen, Verfahren und Verwendungen
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
EP2266592A3 (de) 2007-01-12 2012-08-08 Intercell AG Schützende Proteine von S. agalactiae, Kombinationen davon und Verwendungsverfahren dafür
CA2685805A1 (en) 2007-05-02 2008-11-13 Intercell Ag Klebsiella antigens
EP2012122A1 (de) 2007-07-06 2009-01-07 Medigene AG Strukturproteine von mutierten Parvoviren als Impfstoffe
EP2158211B1 (de) 2007-05-31 2016-08-10 Medigene AG Mutiertes strukturprotein eines parvovirus
EP2511291A3 (de) 2007-06-18 2012-11-07 Intercell AG Chlamydia-Antigene
AU2009226949A1 (en) 2008-03-17 2009-09-24 Intercell Ag Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
CN101980721B (zh) 2008-04-02 2013-03-13 国立大学法人德岛大学 含有合成肽的抗原药物赋形剂和使用其的粘膜疫苗
WO2009155484A2 (en) 2008-06-20 2009-12-23 Wyeth Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains
US20100015171A1 (en) * 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
EP2424882A2 (de) 2009-02-05 2012-03-07 Intercell AG Gegen e.-faecalis schützende peptide, verfahren und anwendungen, die damit in zusammenhang stehen
EP2405938A2 (de) 2009-02-13 2012-01-18 Intercell AG Nicht typisierbare haemophilus influenza-antigene
AU2010264538B2 (en) 2009-06-22 2013-10-03 Wyeth Llc Immunogenic compositions of Staphylococcus aureus antigens
WO2011041003A2 (en) 2009-06-22 2011-04-07 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
AU2010288239B2 (en) 2009-08-27 2014-01-16 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
EP2308896A1 (de) 2009-10-09 2011-04-13 Sanofi-aventis Polypeptides zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten
EP2319871A1 (de) 2009-11-05 2011-05-11 Sanofi-aventis Polypeptide zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten
PH12012500564A1 (en) 2009-10-09 2012-10-22 Sanofi Sa Polypeptides for binding to the receptor for advanced glycation endproducts as well as compositions and methods involving the same
US8765148B2 (en) 2010-02-19 2014-07-01 Valneva Austria Gmbh 1C31 nanoparticles
WO2012020326A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
EP3626263A1 (de) 2010-06-04 2020-03-25 Wyeth LLC Impstoffformulierungen
CA2808975C (en) 2010-08-23 2018-10-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
KR101907434B1 (ko) 2010-09-03 2018-10-12 발네바 오스트리아 게엠베하 C. 디피실의 a 독소 및 b 독소 단백질의 분리된 폴리펩타이드 및 이의 용도
AR082925A1 (es) 2010-09-08 2013-01-16 Medigene Ag Proteinas estructurales mutadas por parvovirus con epitopo de celulas b de proteccion cruzada, producto y metodos relacionados
KR101584871B1 (ko) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
HUE033072T2 (hu) 2010-12-22 2017-11-28 Wyeth Llc Staphylococcus aureus antigének immunogén készítményei
BRPI1100857A2 (pt) * 2011-03-18 2013-05-21 Eduardo Nowill Alexandre agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
ITMI20111182A1 (it) 2011-06-28 2012-12-29 Canio Buonavoglia Vaccino per coronavirus canino
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP2847322B1 (de) 2012-05-08 2019-06-26 Western University Of Health Sciences Standardisierte ex-vivo-plattformen zur antigenspezifischen expansion der cd4+-t-zell-populationen
EA031234B1 (ru) * 2012-10-29 2018-12-28 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Арканзас Вакцина с адъювантом на основе маннозилированного хитозана
RU2672053C2 (ru) 2012-12-20 2018-11-09 Пфайзер Инк. Способ гликоконъюгации
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
US20140271723A1 (en) * 2013-03-15 2014-09-18 Saint Louis University Adjuvant compositions and methods of using thereof
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
WO2016130569A1 (en) 2015-02-09 2016-08-18 Mj Biologics, Inc. A composition comprising pedv antigens and methods for making and using the composition
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
KR102143534B1 (ko) 2015-05-04 2020-08-12 화이자 인코포레이티드 B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도
CN113521007B (zh) * 2016-07-01 2022-11-18 四川大学 抗菌肽衍生物在制备免疫佐剂中的用途
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
JP2020515629A (ja) * 2017-04-04 2020-05-28 アヴィディア テクノロジーズ， インコーポレイテッド 免疫応答を誘導するためのペプチドベースのワクチン、それらの製造方法および使用
CN107266585B (zh) * 2017-07-13 2019-08-06 陕西科技大学 一种mlh融合抗菌肽及其制备方法和应用
CN112074295A (zh) 2018-02-16 2020-12-11 2A制药公司 用于治疗自身免疫性疾病的细小病毒结构蛋白
EP3527223A1 (de) 2018-02-16 2019-08-21 2A Pharma AB Mutiertes parvovirus-strukturprotein
CN109745556A (zh) * 2019-03-01 2019-05-14 龙阔（苏州）生物工程有限公司 一种疫苗佐剂及其应用及猪繁殖与呼吸综合征疫苗
KR20220010478A (ko) 2019-05-20 2022-01-25 발네바 에스이 기도 감염의 치료 또는 예방용 서브유닛 백신
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP2023518809A (ja) * 2020-03-20 2023-05-08 ディグニティー ヘルス アデノ随伴ウイルスの改変方法及び分離方法
WO2021202456A1 (en) * 2020-03-30 2021-10-07 The Wistar Institute Of Anatomy And Biology Synthetic soluble receptor mimics and methods of use for treatment of covid-19
WO2021211279A1 (en) 2020-04-17 2021-10-21 Regents Of The University Of Minnesota SARS-CoV-2 SPIKE RECEPTOR BINDING DOMAIN AND COMPOSITIONS AND METHODS THEREOF
EP4203995A1 (de) 2020-08-26 2023-07-05 Pfizer Inc. Gruppe-b-streptococcus-polysaccharid-protein-konjugate, verfahren zur herstellung von konjugaten, immunogene zusammensetzungen mit konjugaten und verwendungen davon
KR20230167017A (ko) 2021-04-09 2023-12-07 발네바 에스이 인간 메타뉴모 바이러스 백신
WO2023083964A1 (en) 2021-11-11 2023-05-19 2A Pharma Ab Parvovirus structural protein against beta- and gamma-hpv
KR20250054810A (ko) 2022-09-29 2025-04-23 화이자 인코포레이티드 Rsv f 단백질 삼량체를 포함하는 면역원성 조성물
WO2026038177A1 (en) 2024-08-16 2026-02-19 Pfizer Inc. Immunogenic compositions and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995004542A1 (en) * 1993-08-06 1995-02-16 Cytel Corporation Cloning and characterization of the complete mage-1 gene
JP3442824B2 (ja) * 1993-08-30 2003-09-02 理化学研究所 抗菌性ペプチド類
JP3547504B2 (ja) * 1994-11-01 2004-07-28 独立行政法人理化学研究所 新規なポリペプチド及びその用途
CA2293826A1 (en) 1997-06-11 1998-12-17 Brigitte Gicquel Attenuated recombinant mycobacteria useful as immunogens or as vaccine components
WO1999009956A1 (en) 1997-08-29 1999-03-04 Corixa Corporation Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof
CU22700A1 (es) * 1997-09-29 2001-07-31 Ct Ingenieria Genetica Biotech Formulación farmacéutica anti-viral que contiene un péptido de la proteína factor anti-lps de limulus y su uso
US20020072495A1 (en) * 2000-09-21 2002-06-13 Oleg Chertov LL-37 is an immunostimulant
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
AU2004224746B2 (en) 2003-03-24 2009-04-23 Valneva Austria Gmbh Improved vaccines
ES2351489T3 (es) 2003-03-24 2011-02-07 Intercell Ag Vacunas mejoradas.
CA2530062A1 (en) 2003-07-11 2005-01-20 Intercell Ag Hcv vaccines

Also Published As

Publication number Publication date
WO2002032451A1 (en) 2002-04-25
AU1232602A (en) 2002-04-29
ZA200301465B (en) 2004-02-24
IL154605A (en) 2009-05-04
RU2007146372A (ru) 2009-06-20
JP2004511528A (ja) 2004-04-15
SI1326634T1 (sl) 2006-10-31
CZ20031299A3 (cs) 2003-10-15
JP2008222721A (ja) 2008-09-25
CA2426490A1 (en) 2002-04-25
US8900564B2 (en) 2014-12-02
IS2608B (is) 2010-04-15
PL362966A1 (en) 2004-11-02
EP1326634B1 (de) 2006-04-26
SK287618B6 (sk) 2011-04-05
NO20031595D0 (no) 2003-04-08
DK1326634T3 (da) 2006-08-14
BRPI0114994B1 (pt) 2017-11-07
HK1055899A1 (en) 2004-01-30
JP4227407B2 (ja) 2009-02-18
US20130216583A1 (en) 2013-08-22
KR100598302B1 (ko) 2006-07-07
EP1326634A1 (de) 2003-07-16
ATE324116T1 (de) 2006-05-15
CN1248736C (zh) 2006-04-05
HUP0302117A2 (hu) 2003-09-29
AT410635B (de) 2003-06-25
CN1468109A (zh) 2004-01-14
NO330274B1 (no) 2011-03-14
BR0114994A (pt) 2003-09-30
ES2263668T3 (es) 2006-12-16
US20090123486A1 (en) 2009-05-14
AU2002212326B2 (en) 2006-01-05
WO2002032451A8 (en) 2002-05-23
KR20030043993A (ko) 2003-06-02
US8361476B2 (en) 2013-01-29
NZ524532A (en) 2004-10-29
DE60119145T2 (de) 2007-02-01
NO20031595L (no) 2003-06-05
BRPI0114994B8 (pt) 2021-05-25
HU228382B1 (en) 2013-03-28
US20050063978A1 (en) 2005-03-24
IS6722A (is) 2003-02-20
SK5752003A3 (en) 2003-12-02
PT1326634E (pt) 2006-09-29
MXPA03002828A (es) 2003-07-14
CA2426490C (en) 2012-01-31
PL209016B1 (pl) 2011-07-29
CZ303303B6 (cs) 2012-07-25
DE60119145D1 (de) 2006-06-01
RU2328305C2 (ru) 2008-07-10
IL154605A0 (en) 2003-09-17
HUP0302117A3 (en) 2004-11-29

Similar Documents

Publication Publication Date Title
NO20031595L (no) Vaksinesammensetning
IL122754A0 (en) Cyclosporin derivatives their preparation and pharmaceutical compositions containing them
RU2003114434A (ru) Вакцинная композиция
ATE557041T1 (de) Peptid-vakzinen gegen streptokokken der gruppe a
EP1548028A4 (de) Substituierte wt1-peptide
EA199900355A1 (ru) Теломераза обратная тринскриптаза
CY1108570T1 (el) Gd3-μιμητικα πεπτιδια
PT1290013E (pt) Derivados dos peptidos apo-ai/aii
MXPA02000465A (es) Derivados ciclopeptidicos como inhibidores de la integrina alfav beta6.
ATE300619T1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
BR0309491A (pt) Composição de vacina, composição imunogênica, utilização de uma proteìna e7 e anticorpos neutralizantes
DE602004028266D1 (de) Angiogene peptide und ihre verwendungen
WO2003097678A3 (en) Use of the repressor glxr for the synthesis of lysine in corynebacterium glutamicum
EA200100314A1 (ru) Пептидные фрагменты холерного экзотоксина в или энтеротоксина в в качестве адъювантов вакцины
MXPA02012664A (es) Peptidos para la preparacion de vacunas contra bordetella pertussis y bordetella parapertussis.
WO1994004565A3 (en) Ipnv vaccine
NZ508812A (en) Peptides for the prevention or treatment of HIV
DE60124299D1 (de) Peptide aus dem b-glycoprotein des menschlichen herpesvirus-7, besonders anwendbar bei serologischen elisa-nachweisen
EP0290246A3 (de) Impfstoff zur Erzeugung einer gegen Tollwutvirus schützenden immunogenen T-Zellen-Respons
DE69702210D1 (de) Antithrombotische peptide aus den wiederholten sequenzen des typs ii
SE0002738D0 (sv) Electric actuator

Legal Events

Date Code Title Description
PC Change of the owner

Owner name: INTERCELL AG, AT

Effective date: 20120919

PC Change of the owner

Owner name: VALNEVA AUSTRIA GMBH, AT

Effective date: 20140611

MK07 Expiry

Effective date: 20201018